Contact Information

Associate Professor
Clinical Psychiatry
Department of Psychiatry
Columbia University College of Physicians & Surgeons
NYS Psychiatric Institute
1051 Riverside Drive
New York, NY   10032

Phone: 646-774-6160
Fax: 212-568-6171

Membership Information

Membership Category:
Research Scientists

Member Since: 2006


Diana Martinez, M.D.



M.D. Cornell University
B.A.  St. John University

About Me

Dr. Diana Martinez is originally from Texas, and came to New York City for medical school.  She attended Weill Cornell Medical College, where her original plans were to become a primary care physician.  However, during her psychiatry rotation, she met talented and thoughtful psychiatrists and was convinced that searching for connections between the brain and behavior was more compelling than diabetes and hypertension. She then completed her residency in Psychiatry at New York Hospital. Following residency, Dr. Martinez began a research fellowship in Positron Emission Tomography (PET) imaging, which uses radiotracers to image the brain chemistry, at Columbia University.  Using this technology, PET imaging studies can show the changes in neurochemistry that occur in addiction. The goal of these studies is to use PET imaging to direct better treatments for drug addiction by investigating the underlying chemistry and using neuroscience to development treatment approaches.

Research Statement

Diana Martinez, MD, is an Associate Professor of Clinical Psychiatry at Columbia University Medical Center. Her research in using Positron Emission Tomography (PET) to image the neurochemistry of the brain in addiction.  Recent work has focused on imaging the dopamine receptors and dopamine transmission in the striatum in addiction, and the clinical relevance of these outcome measures with respect to drug self-administration and treatment response.  For example, these studies show that response to treatment is predicted by dopamine signaling in the ventral striatum in cocaine abuse and recent work demonstrating that the metabotropic glutamate receptor type 5 (mGluR5) is reduced in cocaine abuse.  Both of these findings have relevance to the question of how neurochemistry may be altered in addiction and how modulating neuroplasticity may be involved in behavioral changes


View Curriculum Vitae